Effective price per mg uses an active dated override first, then the row-level historical discount, then the latest vendor-default policy recorded for that UTC day. Aggregate chart points include exact-comparability offers only. Missing observations remain gaps; the series does not interpolate across unavailable offers or absent snapshots.

Price watch · beta

Let the market come to you.

Watch the best market price or one vendor. Get one email when PEG-MGF crosses your target, drops, or sets a new tracked low—without daily noise.

Public product evidence 12 certificate records for PEG-MGF products, from 8 vendors 4 reference a report on the testing laboratory's own system · 4 have a laboratory lookup that answered when last checked · 12 match a vendor product page at the same address

Status

Research Market

This name primarily lives in the research market and should not be read like an approved pharmaceutical product.

Research area

Performance / anabolic research

Primary research area: Performance. Also surfaces under GH axis for browsing and discovery.

Body systems

Muscle & bone

Where the compound acts, as a browse axis. It is an editorial grouping for discovery, not a claim about labeled indications.

Aliases

Pegylated MGF, PEG Mechano Growth Factor

Signal depth

Medium

No FDA label signal · 498 trials · 0 PubMed results

Anecdotal

Research evidence

There is essentially no indexed clinical or preclinical literature for PEG-MGF. Claims rest on user reports and marketing rather than studies.

PEG-MGF has no clinical trials that name it and 0 PubMed-indexed publications and is not FDA-approved. Note: 1 retracted publication in the literature.

⚠ 1 retracted publication

Human data

Lab / animal only

Trial quality

No human trials

Outcomes

No human trials

Replication

None

Literature

Established

Biomaterials · 123 citations Mechano growth factor (MGF) and transforming growth factor (TGF)-β3 functionalized silk scaffolds enhance articular hyaline cartilage regeneration in rabbit model Mechanisms of Ageing and Development · 87 citations Mechano Growth Factor E peptide (MGF-E), derived from an isoform of IGF-1, activates human muscle progenitor cells and induces an increase in their fusion potential at different ages Experimental Cell Research · 77 citations A new pro-migratory activity on human myogenic precursor cells for a synthetic peptide within the E domain of the mechano growth factor Journal Article The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. Journal Article Mechanical growth factor inhibited syndesmophyte formation and the progression of osteoarthritis and ankylosing spondylitis-like symptoms in HLA-B27/Hu-β2m transgenic rats. Published Erratum Corrigendum to "Surface modification of electrospun fibers with mechano-growth factor for mitigating the foreign-body reaction" [Bioact. Mater. 6 (9) (2021) 2983-2998].

Evidence history

2026-11-07 Preclinical → Anecdotal Band Preclinical → Anecdotal; -194 PubMed
2026-07-09 Preclinical First graded

Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-11-07 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →

What PEG-MGF is

PEG-MGF is a pegylated analogue related to mechano growth factor, a splice variant associated with the IGF-1 system. It is usually framed around muscle repair, hypertrophy interest, or post-training recovery.

Why it matters

It broadens the muscle-growth category beyond IGF-1 LR3 and shows how performance-focused peptide demand often clusters around growth-factor signaling.

Regulatory context

PEG-MGF is not an FDA-approved muscle-building drug in the United States and belongs in the research-market category.

Practical reading note

This is a good example of a peptide where bodybuilding demand can easily outrun evidence quality, so mechanism should not be confused with proof of real-world outcome.